The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients ...

Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM).

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab ...

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...

Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.

Results from the investigational, randomized, open-label IRAKLIA phase 3 study demonstrated that Sarclisa administered at a fixed dose subcutaneously (SC) via an on-body delivery system (OBDS) in ...

In this article, I employ AI to rank 19 repurposed drugs and supplements by effectiveness against metastatic cancer. To add ...

Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies. Click here to find out why I ...

Panelists discuss how minimal residual disease assessment demonstrates superior depth of response with ciltacabtagene autoleucel compared with standard of care in patients who have ...

Daratumumab therapy resulted in superior progression-free survival in frail patients with previously untreated multiple myeloma.